Sokolova MV, Simon D, Nas K, et al. - Researchers intended to establish markers of systemic inflammation in individuals with monomorphic and polymorphic psoriatic skin, entheseal, and joint disease. Researchers compared the selection of serum markers elevated in psoriatic arthritis with healthy controls from a panel of 10 different markers reflecting the pathophysiology of psoriatic disease. They further examined these markers as well as C-reactive protein (CRP) in a larger cohort of 210 individuals- 105 healthy controls and 105 individuals with psoriatic disease with either monomorphic skin (S), entheseal (E) or joint (A) involvement or polymorphic disease with various combinations of skin, entheseal and joint disease (SE, SA, EA, SEA). They sought to examine whether tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitor therapy normalizes these markers. In the majority of individuals, systemic inflammation is detectable with psoriatic disease, even if CRP is normal. It was showed that the respective marker pattern depends on the manifestation of psoriatic disease for skin, entheseal, and joint involvement.